The association of SARS-CoV-2 infection and tuberculosis disease with unfavorable treatment outcomes: A systematic review.

Autor:	Vadlamudi NK; Faculty of Medicine, Department of Pediatrics, The University of British Columbia, Vancouver, Canada., Basham CA; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America., Johnston JC; Faculty of Medicine, Department of Medicine, The University of British Columbia, Vancouver, Canada., Ahmad Khan F; Research Institute of the McGill University Health Centre, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research & Evaluation, Montreal, Canada.; McGill International TB Centre, Montreal, Canada., Battista Migliori G; Istituti Clinici Scientifici Maugeri IRCCS, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Tradate, Italy., Centis R; Istituti Clinici Scientifici Maugeri IRCCS, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Tradate, Italy., D'Ambrosio L; Public Health Consulting Group, Lugano, Switzerland., Jassat W; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Division of Public Health Surveillance and Response, Johannesburg, South Africa.; Right to Care, Pretoria, South Africa., Davies MA; Western Cape Government, Health and Wellness, Cape Town, South Africa.; School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa., Schwartzman K; Research Institute of the McGill University Health Centre, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research & Evaluation, Montreal, Canada.; McGill International TB Centre, Montreal, Canada.; Respiratory Division, McGill University, Montreal, Canada., Campbell JR; Research Institute of the McGill University Health Centre, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research & Evaluation, Montreal, Canada.; McGill International TB Centre, Montreal, Canada.; Department of Medicine & Department of Global and Public Health, McGill University, Montreal, Canada.
Jazyk:	angličtina
Zdroj:	PLOS global public health [PLOS Glob Public Health] 2023 Jul 19; Vol. 3 (7), pp. e0002163. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
DOI:	10.1371/journal.pgph.0002163
Abstrakt:	Background: Whether SARS-CoV-2 infection and its management influence tuberculosis (TB) treatment outcomes is uncertain. We synthesized evidence on the association of SARS-CoV-2 coinfection (Coinfection Review) and its management (Clinical Management Review) on treatment outcomes among people with tuberculosis (TB) disease. Methods: We systematically searched the literature from 1 January 2020 to 6 February 2022. Primary outcomes included: unfavorable (death, treatment failure, loss-to-follow-up) TB treatment outcomes (Coinfection and Clinical Management Review) and/or severe or critical COVID-19 or death (Clinical Management Review). Study quality was assessed with an adapted Newcastle Ottawa Scale. Data were heterogeneous and a narrative review was performed. An updated search was performed on April 3, 2023. Findings: From 9,529 records, we included 11 studies and 7305 unique participants. No study reported data relevant to our review in their primary publication and data had to be contributed by study authors after contact. Evidence from all studies was low quality. Eight studies of 5749 persons treated for TB (286 [5%] with SARS-CoV-2) were included in the Coinfection Review. Across five studies reporting our primary outcome, there was no significant association between SARS-CoV-2 coinfection and unfavorable TB treatment outcomes. Four studies of 1572 TB patients-of whom 291 (19%) received corticosteroids or other immunomodulating treatment-were included in the Clinical Management Review, and two addressed a primary outcome. Studies were likely confounded by indication and discordant findings existed among studies. When updating our search, we still did not identify any study reporting data relevant to this review in their primary publication. Interpretation: No study was designed to answer our research questions of interest. It remains unclear whether TB/SARS-CoV-2 and its therapeutic management are associated with unfavorable outcomes. Research is needed to improve our understanding of risk and optimal management of persons with TB and SARS-CoV-2 infection. Trial Registration: Registration: PROSPERO (CRD42022309818). Competing Interests: The authors have read the journal’s policy and have the following competing interests: NKV reports receiving consulting fees from Broadstreet HEOR for unrelated projects outside of the submitted work. JRC reports receiving consulting fees from the COVID-19 Immunity Task Force (Canada) and The World Bank, for unrelated projects outside of the submitted work. This does not alter our adherence to PLOS policies on sharing data and materials. (Copyright: © 2023 Vadlamudi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu